Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodsyplastic syndromes (MDS).

7020Background: MDS is a challenging disease to treat due to intricate complexities at the molecular and epigenetic levels. AZA is the standard of care for patients (pts) with higher-risk disease, ...